Drug Profile
GRT 6015
Alternative Names: GRT-6015Latest Information Update: 28 Sep 2021
Price :
$50
*
At a glance
- Originator Grunenthal
- Class Antirheumatics; Skin disorder therapies; Small molecules
- Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Psoriasis; Psoriatic arthritis
Most Recent Events
- 28 Sep 2021 No recent reports of development identified for preclinical development in Psoriasis in Germany
- 28 Sep 2021 No recent reports of development identified for preclinical development in Psoriatic-arthritis in Germany
- 16 Aug 2017 Preclinical trials in Psoriasis in Germany (unspecified route)